OverviewSuggest Edit

Evoke Pharma is a pharmaceutical company, primarily focused on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
TypePublic
Founded2007
HQSolana Beach, US
Websiteevokepharma.com

Latest Updates

Employees (est.) (Feb 2019)6(-14%)
Share Price (Jun 2019)$0.7

Evoke Pharma Office Locations

Evoke Pharma has an office in Solana Beach
Solana Beach, US (HQ)
420 Stevens Ave
Show all (1)

Evoke Pharma Financials and Metrics

Evoke Pharma Revenue

USD

Net income (FY, 2018)

(7.6m)

EBIT (FY, 2018)

(8.0m)

Market capitalization (10-Jun-2019)

15.3m

Closing stock price (10-Jun-2019)

0.7

Cash (31-Dec-2018)

5.3m
Evoke Pharma's current market capitalization is $15.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

1.6m3.2m3.7m3.6m4.1m3.9m

R&D expense

957.0k10.0m8.2m7.0m7.1m4.1m

Operating expense total

2.6m13.2m11.8m10.5m11.2m8.0m

EBIT

(2.6m)(13.2m)(11.8m)(10.5m)(11.2m)(8.0m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

976.4k819.7k1.1m802.7k830.1k1.2m872.0k984.0k1.0m917.3k

R&D expense

2.2m1.8m2.0m2.1m1.3m770.7k2.0m2.7m1.4m1.4m

Operating expense total

3.2m2.7m3.2m2.9m2.2m2.0m2.9m3.7m2.4m2.3m

EBIT

(3.2m)(2.7m)(3.2m)(2.9m)(2.2m)(2.0m)(2.9m)(3.7m)(2.4m)(2.3m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

24.2m14.2m8.7m9.0m7.7m5.3m

Accounts Receivable

Inventories

Current Assets

24.4m15.2m9.5m9.3m7.9m5.6m
Quarterly
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(2.8m)(13.2m)(12.1m)(10.7m)(12.2m)(7.6m)

Inventories

Accounts Payable

327.9k866.6k(20.5k)(276.7k)663.2k(440.4k)

Cash From Operating Activities

(3.0m)(11.5m)(10.5m)(8.7m)(8.7m)(7.0m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.2m)(2.7m)(3.2m)(3.0m)(3.0m)(5.1m)

Accounts Payable

1.3m1.0m1.4m1.4m1.3m1.2m1.3m498.1k549.0k
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics

Evoke Pharma Online and Social Media Presence

Embed Graph

Evoke Pharma News and Updates

Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA

SOLANA BEACH, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted a type A meeting request and meeting package to the U.S. Food and Drug Admin…

Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication

SOLANA BEACH, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2018.

Evoke Pharma Receives Preliminary FDA Communication on Gimoti™ NDA

SOLANA BEACH Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), today announced the receipt of a multi-disciplinary review (DR) letter from the U.S. Food and Drug Administration (FDA) in association with the Gimoti 505(b)(2) New Drug Application (NDA). A DR letter is use…

Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners

Novos to provide fully integrated commercial function for Evoke and non-dilutive financing for the commercialization of Gimoti, extending cash runway into 2020

BRIEF-Moshe Arkin Reports 9.11 pct Passive Stake In Evoke Pharma Inc As Of April 30

* MOSHE ARKIN REPORTS 9.11 PERCENT PASSIVE STAKE IN EVOKE PHARMA INC AS OF APRIL 30, 2018 - SEC FILING Source text - https://bit.ly/2jFtovF Further company coverage:

Evoke Pharma Blogs

Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results

Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results Content Import Thu, 08/08/2019 - 05:31 Evoke Pharma to Resubmit Gimoti™ NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results …

Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA

Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA Content Import Tue, 04/02/2019 - 06:05 Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA Ap…

Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA

Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA Content Import Thu, 03/14/2019 - 08:35 Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA Mar 14, 2019 This release is a backfill from a News Wire General …

Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results Content Import Wed, 02/27/2019 - 08:34 Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results Feb 27, 2019 …

Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights

Gimoti ™ NDA submitted to FDA on June 1 st ; awaiting 74-Day FDA filing communication letter Gender-specific patents granted for Gimoti in the European Union and Mexico SOLANA BEACH, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company

Evoke Pharma Frequently Asked Questions

  • When was Evoke Pharma founded?

    Evoke Pharma was founded in 2007.

  • How many employees does Evoke Pharma have?

    Evoke Pharma has 6 employees.

  • Who are Evoke Pharma competitors?

    Competitors of Evoke Pharma include Biogen, MyoKardia and Athersys.

  • Where is Evoke Pharma headquarters?

    Evoke Pharma headquarters is located at 420 Stevens Ave, Solana Beach.

  • Where are Evoke Pharma offices?

    Evoke Pharma has an office in Solana Beach.

  • How many offices does Evoke Pharma have?

    Evoke Pharma has 1 office.